ArticleAmerican journal of translational research2021
Clinical effect and changes of ET-1, FMD and NO levels in the treatment of acute cerebral infarction with acanthopanax injection.
Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Peripheral vascular function in stroke: systematic review and meta-analysis.Journal of applied physiology (Bethesda, Md. : 1985) · 2024Pooled it
- Cognitive Assessments in Randomized Controlled Trials of Acute or Secondary Prevention Stroke Treatments 2011 to 2024: A Scoping Review.Journal of the American Heart Association · 2025Article
- The Predictive Value of PKC and ET-1 Levels in Cerebrospinal Fluid for Vasospasm and Prognosis in Patients with Aneurysmal Subarachnoid Hemorrhage.International journal of general medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore clinical efficacy of acanthopanax injection for the treatment of acute cerebral infarction and its effect on the changes in endothelin-1 (ET-1), flow-mediated vasodilation (FMD) and nitric oxide (NO) levels.
methodsA total of 120 patients with acute cerebral infarction were selected for prospective study. The patients with conventional treatment regimen were the control group while the observation group was treated acanthopanax injection in addition to the treatment given to the control group. Both groups contained 60 patients. After 14 days of treatment, we observed the clinical effects and measured ET-1, NO, FMD, serum C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), National Institute of Health stroke scale (NIHSS), Mini-mental state examination (MMSE) and Montreal Cognitive Assessment (MoCA) in both groups.
resultsThe total effective rate of the observation group was higher than that of the control group (P=0.020). The improvement of ET-1, FMD, NO, CRP, TNF-α and IL-6 in the observation group was superior to that of the control group (P<0.05). The scores of NIHSS, MMSE and MoCA in the observation group were better than those of the control group (P<0.05).
conclusionThe treatment of acute cerebral infarction with acanthopanax injection may enhance the clinical efficacy, improve vascular endothelial function, reduce inflammation and nerve damage, and improve cognitive function.
Indexed as
Identifiers
34017541PMC8129373What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.